Floatz logo

Epirubicin

Neoplasms, Germ Cell and Embryonal

Hoffmann-La RochePhase 3Active
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Neoplasms, Germ Cell and Embryonal cohort.

Asset / SponsorPhaseRating
Pembrolizumab
Hoffmann-La Roche
Phase 3BB
Pralsetinib, trans-
Hoffmann-La Roche
Phase 3BB
Carboplatin
Hoffmann-La Roche
Phase 3B
CIS-DIAMMINEDICHLOROPLATINUM II
Hoffmann-La Roche
Phase 3B
5-Flucytosine
CHA University
Phase 1/2CCC

View all 12 →

Same molecule, other indications

Epirubicin is also rated in:

Recurrent Breast CarcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
Lung Non-Small Cell Squamous CarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
Advanced/Metastatic Gastroesophageal AdenocarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →